[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100378835":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":47,"collaborators":20,"id":50,"slug":20,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"King Saud University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","SABR 35Gy\u002F5 to prostate, up to 50Gy\u002F5 to MR nodule, and 25Gy\u002F5 to pelvic nodes and SVs",[13],"Radiation: Pelvic SABR with intra-prostatic SABR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Pelvic SABR with intra-prostatic SABR","SABR 25Gy \u002F 5 fractions to pelvis; 35Gy \u002F 5 fractions to prostate; up to 50Gy \u002F 5 fractions to MR nodule",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Yasir Alayed, MD","King Saud Medical City","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","+966114671546","yalayed@ksu.edu.sa",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"King Saud University Medical City","RECRUITING","Riyadh","Saudi Arabia","SA",{"type":39,"coordinates":40},"Point",[41,42],46.72185,24.68773,{"lat":42,"lon":41},[45,46],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Dr. Yasir Alayed","Consultant and Assistant Professor","100378835",false,"NCT04212715","Prostate SABR With Intra-Prostatic SABR Boost","Prostate SABR With Intra-Prostatic SABR Boost: A Phase II Study","Inclusion Criteria:\n\n* Histologically confirmed prostate adenocarcinoma\n* High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA \\> 20 ng\u002FmL\n* Willing to give informed consent to participate in this clinical trial\n\nExclusion Criteria:\n\n* Prior pelvic radiotherapy\n* Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease\n* Contraindication to prostate MRI\n* No evidence of castrate resistance (defined as PSA \\\u003C 3 ng\u002Fml while testosterone is \\\u003C 0.7nmol\u002Fl. Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression.\n* Definitive extrapelvic nodal or distant metastatic disease on staging investigations.","MALE","18 Years","99 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","Stereotactic Ablative Radiation (SABR\u002FSBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.",[67],"Prostate Cancer","2019-12-27",{"date":70,"type":71},"2020-01-02","ACTUAL",{"date":73,"type":71},"2019-12-26",{"date":75,"type":61},"2026-12",{"name":5,"class":6},1]